The Role of the Federal Trade Commission in Regulating Non-Prescription Drug Advertising and Promotion

1992 ◽  
Vol 22 (2) ◽  
pp. 265-276 ◽  
Author(s):  
Marianne R. Watts ◽  
Judith D. Wilkenfeld
Keyword(s):  
Prescription Drug ◽  
Drug Administration ◽  
Federal Trade Commission ◽  
Food And Drug Administration ◽  
Over The Counter ◽  
Drug Advertising ◽  
Prescription Drug Advertising ◽  
Advertising And Promotion

The article focuses on the manner in which the Federal Trade Commission regulates advertising in general and over-the-counter drug advertising in particular. It also highlights the cooperation that exists between the Commission and the Food and Drug Administration in both food and drug matters.

Direct-to-Consumer Prescription Drug Advertising

1999 ◽  
Vol 25 (1) ◽  
pp. 149-167
Author(s):  
Tamar V. Terzian
Keyword(s):  
Prescription Drug ◽  
Drug Administration ◽  
Food And Drug Administration ◽  
Pharmaceutical Products ◽  
Drug Advertising ◽  
Direct To Consumer ◽  
Prescription Drug Advertising ◽  
Adequate Provision ◽  
Package Labeling ◽  
Made In

The Food and Drug Administration (FDA) regulates the promotion of pharmaceutical products. The FDA's regulations issued under the Food, Drug and Cosmetic Act (FDCA) require that prescription drug broadcast advertisements include the following: (1) a major statement of the product's risks in at least the audio part of the advertisement; and (2) that an adequate provision for the dissemination of the approved package labeling be made “in connection with the broadcast presentation,” if the brief summary is not also part of the advertisement. Under the FDCA, the brief summary provides information concerning the major risks of the drug.

The Role of the Federal Trade Commission in Regulating Over-the-Counter Drug Advertising

1974 ◽  
Vol 4 (3) ◽  
pp. 232-237
Author(s):  
Thomas J. Donegan
Keyword(s):  
Drug Abuse ◽  
Empirical Research ◽  
Federal Trade Commission ◽  
Primary Concern ◽  
Over The Counter ◽  
Drug Advertising

Mr. Donegan's presentation touches upon some of the legislative and administrative problems facing the FTC in reviewing unfair practices in drug advertising. The FTC's primary concern is with the truthfulness of advertising practices and is now requiring substantiation of drug claims. Mr. Donegan sees a move in the direction of reviewing the possible relations between drug advertising and drug abuse. He actively encourages empirical research to substantiate this charge.

Sign in / Sign up

Export Citation Format

Share Document